Skip to main
OKUR
OKUR logo

OKUR Stock Forecast & Price Target

OKUR Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OnKure Therapeutics reported a net loss of $1.14 per share for the second quarter of 2025, which is an improvement over the company's earlier estimate of a $1.22 per share loss. This narrower loss indicates a potentially strong financial management and execution in their clinical research segment. Additionally, the favorable safety profile of their lead candidate, OKI-219, which demonstrated no severe adverse events and high tolerability, underscores the promising therapeutic potential of the company's precision medicine approach in treating underserved cancers.

Bears say

OnKure Therapeutics Inc. is projected to incur a net loss of $4.56 per share in 2025, a slight improvement from the previous estimate of $4.75 per share, which indicates ongoing financial challenges. The company's negative outlook is significantly influenced by potential risks, including negative clinical results from its lead asset, OKI-219, and delays in advancing its pipeline candidates, which could hinder future revenues. Additionally, uncertainties surrounding regulatory approvals, competition from other therapies, and the risk of long-term dilution further exacerbate concerns regarding the company's financial viability.

OKUR has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OnKure Therapeutics Inc (OKUR) Forecast

Analysts have given OKUR a Buy based on their latest research and market trends.

According to 4 analysts, OKUR has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OnKure Therapeutics Inc (OKUR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.